Cargando…

Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings, increased overall survival (OS) with individual variability of toxicity. Pharmacogenomic guidelines recommended pre-treatment ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bruera, Gemma, Ricevuto, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678498/ https://www.ncbi.nlm.nih.gov/pubmed/33235483 http://dx.doi.org/10.2147/PGPM.S253586

Ejemplares similares

Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2020)

Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
por: Bruera, Gemma, et al.
Publicado: (2020)

Clinical parameters to guide decision-making in elderly metastatic colorectal cancer patients treated with intensive cytotoxic and anti-angiogenic therapy
por: Bruera, Gemma, et al.
Publicado: (2016)

Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
por: Bruera, Gemma, et al.
Publicado: (2019)

Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
por: BRUERA, GEMMA, et al.
Publicado: (2014)

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
por: BRUERA, GEMMA, et al.
Publicado: (2013)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment
por: Bignucolo, Alessia, et al.
Publicado: (2017)

KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
por: Bruera, Gemma, et al.
Publicado: (2018)

Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)
por: Bruera, Gemma, et al.
Publicado: (2013)

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study
por: Bruera, Gemma, et al.
Publicado: (2010)

Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice
por: Bruera, Gemma, et al.
Publicado: (2021)

The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?
por: Simões, Ana Rita, et al.
Publicado: (2020)

Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study
por: Guadagni, Stefano, et al.
Publicado: (2020)

Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases
por: Guadagni, Stefano, et al.
Publicado: (2022)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Pharmacogenomics of Hypertension Treatment
por: Rysz, Jacek, et al.
Publicado: (2020)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
por: Bruun, Jarle, et al.
Publicado: (2018)

Pharmacogenomic Approaches to Asthma Treatment
por: Cho, Sang-Heon
Publicado: (2010)

Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update
por: Ab Mutalib, Nurul-Syakima, et al.
Publicado: (2017)

Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019)

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review
por: Wang, Ching-Ya, et al.
Publicado: (2023)

Assessment of pharmacogenomic agreement
por: Safikhani, Zhaleh, et al.
Publicado: (2016)

Pharmacogenomics of Antibiotics
por: Stocco, Gabriele, et al.
Publicado: (2020)

Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice
por: Bruera, Gemma, et al.
Publicado: (2019)

The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
por: Williams, Paula Juliet, et al.
Publicado: (2012)

Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
por: Patel, Jai N
Publicado: (2016)

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study
por: Bruera, Gemma, et al.
Publicado: (2018)

Role of pharmacogenomics in the treatment of tuberculosis: a review
por: Ramachandran, Geetha, et al.
Publicado: (2012)

Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?
por: Pearson, Ewan R.
Publicado: (2019)

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis
por: Lim, Sung Ho, et al.
Publicado: (2022)

Implications of Pharmacogenomics in the Current and Future Treatment of Asthma
por: Morrow, Thomas J.
Publicado: (2007)

Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer
por: Bruera, Gemma, et al.
Publicado: (2018)

Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use
por: Ramli, Fitri Fareez
Publicado: (2021)

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
por: Varnai, Reka, et al.
Publicado: (2019)

Pharmacogenomics of Cancer Pain Treatment Outcomes in Asian Populations: A Review
por: Satkunananthan, Shobha Elizabeth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rlnul3vuni0dlj4hd5k1tbvhh4